Indaptus Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2000-01-01

Employees: 7

Market Cap: -

Website: http://indaptusrx.com

Introduction: Intec Parent, Inc. develops pharmaceutical products. The company is headquartered in Jerusalem, Israel.

Clinical Trials

Active:0

Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1

1 (100.0%)

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult
HCC - Hepatocellular Carcinoma
CRC (Colorectal Cancer)
Pancreatic Adenocarcinoma
NSCLC Non-small Cell Lung Cancer
Squamous Cell Cancer of the Head and Neck
UC (Urothelial Cancer)
MSI-H Cancer

Interventions: Drug: Decoy20
Drug: Tislelizumab

First Posted Date: 2022-12-14

Last Posted Date: 2025-04-04

Lead Sponsor: Indaptus Therapeutics, Inc

Target Recruit Count: 120

Registration Number: NCT05651022

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
UH Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
University of Southern California- Norris Cancer Center, Los Angeles, California, United States

and more 9 locations

News

Health Canada Approves Expansion of Decoy20 Cancer Immunotherapy Trial

6 months ago

Indaptus Therapeutics receives Clinical Trial Authorization from Health Canada to expand its ongoing U.S. clinical trial INDP-D101 for its lead cancer immunotherapy candidate Decoy20.

Incyte and Indaptus Announce Key Milestones and Strategic Goals for 2025

7 months ago

Incyte anticipates a transformational 2025 with multiple potential drug launches and pivotal trial readouts across its oncology and inflammation & autoimmunity portfolio.